The Future of Immunization: Technology and Trends

Updated August 6, 2026.

Immunization has played a significant role in the healthcare industry, especially due to the COVID-19 pandemic of 2020. Following the pandemic in 2022, the Biden administration requested $88.2 billion over five years for pandemic preparedness and biodefense, underscoring how immunization became central to national health security planning.

With how much immunization has progressed in recent years, where is the future of immunization heading? Let’s take a look at new methods and trends for this essential aspect of the healthcare industry.

New Vaccine Development Techniques

As we saw during the pandemic, new methods of developing vaccines have emerged—we’ve all heard about the COVID mRNA vaccines, but that’s not the only new method on the market.

According to a study by Rand Health Quarterly, nanoparticle (NP) vaccines, viral-like particle (VLP) vaccines, and universal vaccines are also beginning to take shape.

Whew, that’s a lot of new terms at once. Don’t worry—up next is a breakdown of each type, as well as the development behind them.

mRNA Vaccines

An mRNA vaccine is where mRNA is used instead of subunits of pathogens. These vaccines work by introducing a piece of mRNA that corresponds to a viral protein that the immune system recognizes as foreign, so it produces antibodies to fight against the infection.

With COVID vaccines jumpstarting this new method, mRNA technology is paving the way for new vaccines that are quicker and easier to modify and develop against emerging viruses.

In fact, Moderna’s personalized mRNA cancer vaccines can be developed in as little as six to eight weeks, and clinical trial results have shown a 49% reduction in the risk of melanoma recurrence or death when combined with immunotherapy.

NP and VLP Vaccines

NP and VLP vaccines are alternative vaccine approaches that offer increased stability and immunogenicity compared to vaccines that use subunits of a pathogen.

NP vaccines work by encapsulating antigens needed to bring about an immune response in a simpler, safer, and more efficient way than conventional or live-attenuated vaccines are capable of.

NP vaccines may also get rid of the need for vaccines to be injected, as these can be administered nasally or through an inhaler. VLP vaccines, a subset of NP vaccines, do not have any viral genetic material but are made with virus-like molecules that mimic the virus.

Because of this, the VLPs are unable to replicate in cells but are still able to trigger an immune response. This offers increased suitability for people with weakened immune systems who would otherwise be at risk of contracting a disease through conventional vaccines.

Universal Vaccines

Universal vaccines can counter multiple variants of a specific disease. This is achieved by displaying a specific protein presented by multiple variants of that disease, which triggers an immune response.

Multiple efforts are underway to develop a universal influenza vaccine, with trials currently displaying promising results. If successful, the vaccine will provide longer-lasting protection against a variety of seasonal influenza viruses and influenza viruses with pandemic potential.

Although there aren’t yet any universal vaccines approved for public use, these vaccines show promise in remaining effective despite pathogen mutations, which means they’ll require few or no booster shots.

New Delivery Techniques

In addition to new development methods, there’s also been great strides in how these vaccines are delivered and administered.

Unlike in the past, a vaccine no longer means you’ll need a shot. As mentioned earlier, inhaled vaccines are already in development in some cases—influenza vaccines have been made in a nasal spray and are available every year to fight seasonal flu.

Another delivery method in the works is a patch application, which consists of extremely tiny needles that deliver a vaccine without the use of a syringe. This could be especially useful in remote areas, as its application wouldn’t need a trained medical professional.

A delivery issue that researchers are also trying to address is the cold-chain problem. Many vaccines need cool storage temperatures to stay viable. But temperature-controlled storage is often unavailable in the parts of the world where vaccination is vital for disease control.

An approach to this problem is finding new methods of storage that reduce dependence on refrigeration and simplify vaccine distribution. Researchers have explored technologies capable of keeping vaccine materials stable at higher temperatures for extended periods.

More recently, a fridge-free tetanus-diphtheria vaccine entered its first human clinical trial in 2025 through the National Institute for Health and Care Research (NIHR). This highlights the continued progress toward reducing reliance on refrigerated storage and improving vaccine access worldwide.

ALSO READ: Are You Prepared to Staff Flu Season?

Ready to Help the Future of Immunization?

The future of immunization depends on the success of medical research for vaccines that:

are simpler to administer
survive transport even without refrigeration
provide a more substantial and long-lasting immune response

Are you ready to make your mark on the healthcare sphere by leading progress towards a stronger future of immunization? Insight Global helps healthcare organizations build the teams and capabilities needed to support innovation, from medical research and clinical operations to technology, data, and AI initiatives.

Whether you need specialized talent, consulting expertise, or support with emerging healthcare technologies and AI solutions, we can help you move critical projects forward. Contact our team today to get started.